Azacitidine

Form: Injectable

Strength: 100 mg/vial

Reference Brands: Vidaza®(EU & US)

Category: Oncology Cancer Care

Azacitidine 50 mg and 100 mg Vials are essential treatments for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Available under the brand name Vidaza®, Azacitidine is a hypomethylating agent that plays a critical role in restoring normal blood cell production in patients with MDS or AML. It works by inhibiting DNA methylation, leading to the reactivation of growth-controlling genes. Azacitidine is available in subcutaneous and intravenous injection forms in 50 mg and 100 mg vials, and is crucial in oncology B2B portfolios focused on blood cancers and hematologic malignancies.